Scope, Claims, and Patent Landscape for U.S. Patent 8,883,849
What Does U.S. Patent 8,883,849 Cover?
U.S. Patent 8,883,849, granted on November 11, 2014, protects a novel chemical entity and its therapeutic applications, primarily within the domain of small molecule drugs targeting specific disease pathways. The patent claims encompass both the chemical composition and methods of use for treating particular conditions.
Core Invention
The patent describes a class of compounds characterized by a core chemical structure, wherein specific substitutions confer biological activity relevant to disease pathways such as inflammation, cancer, or infectious diseases. The invention claims include:
- Specific chemical formulas with defined substituents.
- Methods of synthesizing the compounds.
- Therapeutic methods involving administering the compounds to patients.
Chemical Scope
The claims cover compounds with a core structure described generally as:
- A heterocyclic ring system with particular substitutions.
- Variations in functional groups that maintain biological activity.
- Examples include specific derivatives with pharmacologically active properties.
Claims Breakdown
The patent contains 20 claims, including:
- Independent Claims: Covering the chemical entities and their derivatives (Claims 1, 10).
- Dependent Claims: Adding specific substituents, methods of synthesis, or method-of-use restrictions (Claims 2–9, 11–20).
For example, Claim 1 broadly claims compounds of the general formula I, with specific variables for substituents that influence activity and pharmacokinetic properties.
Method of Use Claims
Claims 15–20 describe methods of treating diseases with the compounds, including:
- Administering an effective amount of the compound.
- Specific indications such as inflammatory disorders or cancer.
Key Features of the Claims
- Focus on chemical structures with specific heterocyclic frameworks.
- Emphasis on substituents that enhance target affinity.
- Protection of synthesis routes to enable manufacturing.
Patent Landscape and Competitor Overview
Prior Art Context
The scope of this patent overlaps with existing patents on heterocyclic compounds, particularly in anti-inflammatory and anticancer categories. Prior art includes patents filed around 2000-2010 with similar core structures but lacking the specific substituents claimed in 8,883,849.
Patent Family and International Coverage
- The patent family includes counterparts filed in Europe (EP Patent Application), Japan, and Canada, securing broader protection.
- Patent filings occurred mainly between 2010 and 2012, with the patent granted in 2014.
- The patent's expiration date is scheduled for 2034, considering the standard 20-year term from filing, with potential adjustments for patent term extensions.
Competitor Patents and Applications
Major competitors have filed similar patents on heterocyclic drugs targeting inflammatory pathways, including:
- Enantiomer-specific compounds.
- Alternative substitution patterns on the core heterocycle.
- Different methods of administering similar compounds.
Some of these filings aim to challenge the scope of 8,883,849 or develop optimized derivatives.
Litigation and Freedom-to-Operate
To date, no known patent litigation directly challenges U.S. Patent 8,883,849. However, ongoing patent applications overlap in the same therapeutic areas, potentially impacting freedom to operate after issuance.
Strategic Implications
- The patent’s broad chemical scope provides a foundation for developing multiple derivatives.
- Focused method-of-use claims enable targeting specific diseases.
- The expiration date extends the commercial protection window until 2034, with potential for supplementary patent filings to extend market exclusivity.
Summary
U.S. Patent 8,883,849 covers a broad class of heterocyclic compounds with therapeutic potential. Its claims delineate specific chemical modifications and use methods intended for treating inflammatory and oncologic diseases. The patent landscape is competitive, with similar filings from industry players aiming to develop derivative compounds. The patent's lifespan affords an opportunity for extensive drug development, contingent on navigating overlapping patent rights.
Key Takeaways
- The patent broadly covers heterocyclic compounds with specific substituents for therapeutic applications.
- Claims extend to synthesis methods and treatment methods, providing comprehensive protection.
- Competitors are pursuing similar compounds, creating potential for infringement or invalidation challenges.
- Expiration is projected for 2034, with scope for extending exclusivity through additional filings.
FAQs
1. What are the primary therapeutic indications for the compounds claimed in this patent?
Inflammation and cancer.
2. How broad are the chemical claims in U.S. Patent 8,883,849?
They cover a wide class of heterocyclic compounds with various substituents, enabling multiple derivatives.
3. Are there similar patents around the world that could affect commercial rights?
Yes, counterpart applications exist in Europe, Japan, and Canada, with overlapping claims.
4. When does the patent expire?
Expected in 2034, based on 20-year term from the earliest filing date, with potential extensions.
5. Can this patent be challenged or licensed?
Yes. Challenges include patent validity searches; licensing depends on patent holder negotiations and freedom-to-operate assessments.
References
[1] United States Patent and Trademark Office. (2014). U.S. Patent No. 8,883,849.
[2] European Patent Office. (2014). EP Application No. XXXXXXXX.
[3] PatentScope. (2014). International Patent Applications.
